Oral Semaglutide (Wegovy) 50 mg effectively manages chronic weight in adults with overweight or obesity across OASIS trials.

Obesity is a growing public health crisis, significantly increasing the risk for cardiometabolic disorders, osteoarthritis, and certain cancers. Traditional interventions often fall short, necessitating more effective pharmacological strategies. Glucagon-like peptide-1 (GLP-1) receptor agonists, initially approved for type 2 diabetes mellitus (T2DM), have emerged as powerful tools for long-lasting weight reduction. This class of drugs, including semaglutide, has transitioned from diabetes-specific therapies to broader weight management, addressing a critical unmet need in patient care.

This literature review summarized the therapeutic efficacy and clinical safety profiles of once-daily oral semaglutide across the OASIS 1, 2, 3, and 4 trials. The reviewed trials primarily compared oral semaglutide 50 mg or 25 mg versus placebo in adults who were overweight or obese, with and without T2DM. OASIS 1 and 2 focused on participants without T2DM and with/without T2DM respectively. OASIS 3 specifically evaluated oral semaglutide 50 mg in 200 Chinese adults with obesity/overweight and comorbidities, while OASIS 4 assessed oral semaglutide 25 mg in patients without T2DM.

The comprehensive review of the OASIS trials demonstrated that once-daily oral semaglutide consistently exhibited therapeutic efficacy for chronic weight management. Across the studies, oral semaglutide was evaluated for its ability to induce significant weight reduction and improve related cardiometabolic parameters in diverse populations of adults with overweight or obesity. The trials also assessed the clinical safety profile of oral semaglutide, identifying its tolerability in these patient groups. This collective evidence supported the approval of oral semaglutide (Wegovy) for weight loss, expanding its utility beyond T2DM management. The findings underscored the role of GLP-1 receptor agonism in addressing the complex pathophysiology of obesity. > Oral semaglutide, as summarized from the OASIS trials, has emerged as a promising drug for long-lasting weight reduction and blood glucose control, surpassing traditional methods for many patients.